Skip to main content

Table 2 Antiemetic regimen

From: 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study

  5HT3RA   N(%) Dexamethasone N(%)
FOLFOX Palonosetron Day1 60 (75.9) Day1 4 (6.7)
    Day1–3 56 (93.3)
  1st generation 5HT3RA Day1 19 (24.1) Day1 7 (36.8)
   Day1–3 12 (63.2)
CAPOX palonosetron Day1 72 (92.3) Day1 2 (2.8)
    Day1–3 70 (97.2)
  1st generation 5HT3RA Day1 6 (7.7) Day1 2 (33.3)
   Day1–3 4 (66.7)
CBDCA + ETP 1st generation 5HT3RA Day1 34 (100.0) Day1–3 34 (100.0)
CBDCA + PTX 1st generation 5HT3RA Day1 58 (100.0) Day1 57 (98.3)
(Lung Cancer)   Day1–3 1 (1.7)
CBDCA + PEM palonosetron Day1 9 (18.7) Day1 7 (77.8)
    Day1–3 1 (11.1)
    Day1–4 1 (11.1)
  1st generation 5HT3RA Day1 39 (81.3) Day1 31 (79.5)
   Day1–2 1 (2.6)
   Day1–3 7 (17.9)
CBDCA + PTX palonosetron Day1 1 (2.2) Day1 1 (2.2)
(Ovarian Cancer) 1st generation 5HT3RA Day1 42 44 (97.8) Day1 33 (73.3)
   Day1–3 2 Day1–3 11 (24.4)
DTX + CPA palonosetron Day1 11 (27.5) Day1 5 (45.5)
    Day1–3 1 (9.1)
    Day1–4 5 (45.5)
  1st generation 5HT3RA Day1 29 (72.5) Day1 1 (3.4)
   Day1–3 1 (3.4)
   Day1–4 27 (93.1)
  1. 5HT3RA 5-hydroxytryptamine-3 receptor antagonist, FOLFOX Oxaliplatin with fluorouracil and folinic acid
  2. CAPOX Capecitabine plus oxaliplatin therapy, CBDCA Carboplatin, ETP Etoposide, PTX paclitaxel
  3. PEM Pemetrexed, DTX Docetaxel, CPA Cyclophosphamide